Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Research, Sickle Cell Disease, Clinical Practice (Health Services and Quality), Clinical Research, Education, Hemoglobinopathies, Diseases, Real-world evidence, Treatment Considerations, Biological therapies, Registries
Hematology Disease Topics & Pathways:
Research, Sickle Cell Disease, Clinical Practice (Health Services and Quality), Clinical Research, Education, Hemoglobinopathies, Diseases, Real-world evidence, Treatment Considerations, Biological therapies, Registries
Monday, December 9, 2024: 4:30 PM-6:00 PM
Room 11
(San Diego Convention Center)
Co-chairs:
Alexis Thompson, MD, MPH, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania
and
Ted Wun, MD, Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center
Disclosures:
Thompson: Beam Therapeutics: Consultancy, Research Funding; Editas: Consultancy, Research Funding; Novartis: Research Funding; CRISPR/Vertex: Consultancy, Research Funding; Global Blood Therapeutics: Divested equity in a private or publicly-traded company in the past 24 months; bluebird bio: Consultancy, Research Funding. Wun: Pfizer, Inc: Membership on an entity's Board of Directors or advisory committees.
During this 90-minute special-interest session, sickle cell disease (SCD) registry and real-world evidence (RWE) leaders will discuss progress across numerous SCD data initiatives, including the ASH Research Collaborative's SCD Data Hub and other federal and non-federal programs. Specific topics include examples of using real-world data (RWD) to generate RWE, how RWD can be used to monitor clinical practice and outcomes for patients who receive cell and gene therapies, various approaches to ensuring data quality when using electronic health record data (EHR), federal priorities related to RWE generation that supports regulated research, and a new project to increase SCD-specific data standards with EHRs.
See more of: Special-Interest Sessions